Retatrutide cut body weight by a quarter in its phase 3 obesity trial

Retatrutide is a once-weekly injection that activates three gut and metabolic hormone receptors at once — those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon [s1]. Its first full phase 3 obesity trial, TRIUMPH-1, has now been published, and the headline number is large: at the highest dose, participants lost a quarter of their body weight over 80 weeks [s1]. The result cements retatrutide among the most potent weight-loss drugs yet tested, while leaving the usual questions about tolerability, durability and cost for later.

What the trial did

TRIUMPH-1 was a phase 3, randomised, double-blind trial in adults with obesity but without diabetes, registered as NCT05929066 [s1][s2]. Participants were assigned to a once-weekly subcutaneous injection of retatrutide at 4 mg, 9 mg or 12 mg, or to placebo, for 80 weeks [s1]. A total of 2339 participants underwent randomisation [s1]. The co-primary outcomes were the percent change in body weight and, in pre-specified subgroups, the change in knee pain among the 574 participants with knee osteoarthritis and the change in the apnoea-hypopnoea index among the 243 with obstructive sleep apnoea [s1].

Weight loss

The mean percent change in body weight was -17.6% at the 4-mg dose, -23.7% at 9 mg and -25.0% at 12 mg, versus -3.9% with placebo [s1]. For the two highest doses tested against placebo, that works out to differences of -19.8 and -21.0 percentage points, respectively (p<0.001 for both) [s1]. A 25% average reduction is in the territory previously associated with bariatric surgery rather than medication, which is why retatrutide has drawn so much attention. The dose-response was clear: each step up, from 4 mg to 9 mg to 12 mg, added further weight loss, which is the pattern a genuine drug effect produces and helps distinguish it from chance [s1].

What may set retatrutide apart from GLP-1-only drugs is the third target. Adding glucagon-receptor activity is thought to raise energy expenditure as well as curb appetite, and the size of the weight loss here is consistent with that extra mechanism pulling in the same direction — though this trial was not designed to isolate how much each of the three receptors contributed [s1].

Beyond the scales

The trial also tracked two conditions that track closely with excess weight. Among participants with knee osteoarthritis, pain scores on a 1-to-10 scale (higher is worse) fell more with retatrutide than placebo: for the intention-to-treat analysis the changes were -3.4, -3.9 and -4.1 across the three doses versus -2.5 with placebo (differences of -1.4 and -1.6 points for the higher doses; both p<0.001) [s1]. Among those with obstructive sleep apnoea, breathing interruptions per hour fell by -22.8, -34.3 and -32.1 events across the doses versus -9.6 with placebo in the intention-to-treat analysis (both higher-dose comparisons p<0.001) [s1]. The most common adverse events were gastrointestinal — nausea, vomiting and diarrhoea — the familiar signature of this drug class [s1].

How to read it

Three cautions temper the headline. First, this is a trial of what the drug does over 80 weeks, not a verdict on lifelong use; weight regain after stopping incretin-based drugs is well documented, and TRIUMPH-1 does not address what happens when treatment ends [s1]. Second, the comparison is against placebo, not against the GLP-1 drugs already on the market, so the trial shows retatrutide works, not that it is better than existing options for any given person. Third, the trial was funded by Eli Lilly, retatrutide's manufacturer, and several authors are company employees [s1] — standard for a registration trial, but a reason to lean on the pre-specified endpoints and the independent regulatory review to come rather than on framing.

An accompanying NEJM commentary argues that obesity trials should be judged on more than the single percentage of weight lost, pressing for closer attention to what happens to participants' health and safety beyond the headline figure [s3]. That is the right lens here: a drug this powerful raises questions about muscle loss, nutritional adequacy and who stays on it, none of which a weight curve answers [s3].

What to watch

Retatrutide still needs regulatory review, and the questions that matter most for patients — durability after stopping, head-to-head performance against semaglutide and tirzepatide, long-term safety, and price — sit outside this trial [s1]. What TRIUMPH-1 establishes is narrower but solid: in adults with obesity and no diabetes, a triple-receptor agonist produced weight loss at the upper edge of what drugs have achieved, alongside measurable improvements in two weight-linked conditions [s1].

Sources

• [s1] Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, 29 September 2026. https://doi.org/10.1056/NEJMoa2604169
• [s2] A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). ClinicalTrials.gov, NCT05929066. https://clinicaltrials.gov/study/NCT05929066
• [s3] Beyond Percentage of Weight Lost — Protecting Participants in Obesity Trials. New England Journal of Medicine, 3 October 2026. https://doi.org/10.1056/NEJMp2609407